

i. Declaration

I, Mercy Juliet Mkandawire declare that this research report is my own unaided work. It is being submitted for the degree of Master of Medicine in Internal Medicine in the University of the Witwatersrand, Johannesburg. It has not been submitted before for any degree or examination at this or any other University.

Mercy J. Mkandawire

_____day of January, 2015

ii. Publications and presentations arising from this study

Abstract accepted for poster presentation at World Congress of Nephrology 2015.

iii. Abstract

Available literature on primary minimal change nephropathy (MCN) predominantly reflects Western and Asian populations, with little data describing the disease in black patients. We therefore studied the demographic and clinical profile of patients presenting with MCN at the Witwatersrand Academic Complex.

The results of 1,618 renal biopsies performed at our centre between 2001 and 2010 were reviewed; 47 patients with MCN were identified (prevalence of 2.9%). The patients were predominantly of black race (83%), the male : female ratio was 1.04:1 and the mean age was 31.8 ± 12.1 years. The majority of patients (90%) fitted the criteria for the nephrotic syndrome. 18% of patients had elevated serum creatinine levels and 6.4% had associated hypertension. An association was found between gender and age; with a predominance of males amongst younger patients (less than 30 years) compared to a predominance of females amongst the older patients. Records of treatment and outcomes were available for 28 patients, all of whom received initial corticosteroid therapy (average dose of prednisone 0.8mg /kg/day). The average duration of therapy was 29 weeks. 57.1% achieved remission with no further relapse. No clinical or demographic parameters were identified that predicted response to corticosteroid therapy. 39.2% of patients had probable steroid dependance/resistance. Of these patients, 58.3% had a single relapse and 41.7% had double relapses. The mean time to relapse was 27.8 ± 19.4 months with 83% of patients relapsing within 48 months; the mean time to relapse was longer in males (39.3 ± 17.5 months) as compared to females who relapsed in 18 ± 16.9 months, which was significant at the 10% level ($P = 0.09$).

MCN is rare amongst Black Africans but should be considered in the differential diagnosis of nephrotic syndrome. The disorder in these patients may be less responsive to corticosteroids and a longer course of therapy may be required to induce remission. Males may be more likely to remain in remission for a longer time period.

iv. Acknowledgements

My sincere gratitude goes to:

My supervisors Professor S. Naicker and Dr Malcolm Davies for their invaluable guidance, encouragement and assistance with the study and the completion of this research report.

Colleagues in the Departments of Nephrology of the Witwatersrand Academic Complex and the National Histopathology Laboratory Service for making this study possible.

v. Contents

i. Declaration	ii
ii. Publications and presentations arising from this research	iii
iii. Abstract	iv
iv. Acknowledgements	vi
v. Contents	vii
vi. List of tables	viii
vii. List of figures	ix
viii. Nomenclature	x
1. Introduction	1
1.1 Background	1
1.2 Epidemiology	4
1.3 Pathogenesis	7
1.4 Diagnosis	11
1.4.1 Clinical features	11
1.4.2 Histopathology	13
1.5 Treatment	16
1.6 Prognosis	19
1.7 Rationale for study	19
1.8 Hypothesis and Aims	20
1.8.1 Hypothesis	20
1.8.2 Aims and Objectives	20
2. Methods and Material	21
2.1 Study design	21
2.2 Selection of patients	22
2.3 Inclusion criteria	23
2.4 Exclusion criteria	23
2.5 Statistical analysis	24
3. Results	25
3.1 Prevalence	25
3.2 Demographic data	25
3.3 Treatment outcomes	31
4. Discussion	37
5. Conclusions	43
6. Limitations	44
7. Appendix	45
7.1 Data collection sheet	45
7.2 Ethics clearance certificate	46
7.3 Permissions	47
8. References	48

vi. List of Tables

Table 1. Secondary Causes of Minimal Change Nephropathy	2
Table 2. The Trend of Prevalence of Minimal Change Nephropathy in Africa	5
Table 3. Relative Frequency of Presenting Clinical Features in Patients with MCN	13
Table 4. Baseline Clinical Characteristics of 47 Patients with Minimal Change Nephropathy	26
Table 5. Comparison of Presenting Characteristics by Gender	28
Table 6. Comparison of Presenting Characteristics between Age Groups	29
Table 7. Comparison of Presenting Characteristics between Race Categories	30
Table 8. Comparison of Gender and Race vs Age in Patients presenting with Minimal Change Nephropathy	31
Table 9. Comparison of Race vs Gender in Patients presenting with Minimal Change Nephropathy	31
Table 10. Association between Clinical Characteristics and Relapse	32
Table 11. Remission Intervals	34

vii. List of Figures

Figure 1. Ultrastructure of the Glomerular Capillary Wall	7
Figure 2. The Glomerular Filtration Barrier	9
Figure 3A. Light Microscopy of Normal Glomerulus	14
Figure 3B. Light Microscopy of Minimal Change Nephropathy	14
Figure 4. Electron Microscopy in Minimal Change Nephropathy	15
Figure 5. Age Distribution of Patients with Minimal Change Nephropathy	27
Figure 6. Comparison of Albumin and UPCR by Gender	28
Figure 7. Comparison of Albumin and UPCR levels between Age Groups	29
Figure 8. Time to First Relapse	33
Figure 9. Remission period according to Gender	35
Figure 10. Remission profiles according to Age Groups	36

viii. Nomenclature

ACE – Angiotensin Converting Enzyme

ARB – Angiotensin Receptor Blocker

CMJAH – Charlotte Maxeke Johannesburg Academic Hospital

FP – Foot Process

FSGS – Focal Segmental Glomerulonephritis

GBM – Glomerular Basement Membrane

GPF – Glomerular Permeability Factor

HJH – Helen Joseph Hospital

HIV – Human Immunodeficiency Virus

IgAN – IgA Nephropathy

MN – Membranous Nephropathy

MCGN – Mesangiocapillary Glomerulonephritis

MPGN – Mesangioproliferative Glomerulonephritis

MCN - Minimal Change Nephropathy

MMF – Mycophenolate Mofetil

NHLS – National Health Laboratory Service

NSAIDS – Non Steroidal Anti Inflammatory Drugs

SLE – Systemic Lupus Erythematosus

UPCR – Urine Protein:Creatinine Ratio